本文選題：結(jié)核/肺 + 藥物敏感試驗(yàn)��； 參考：《實(shí)用醫(yī)學(xué)雜志》2014年14期

【摘要】：目的:了解耐多藥結(jié)核分枝桿菌對(duì)氧氟沙星(Ofx)、卡那霉素(Km)二線抗結(jié)核藥物的耐藥情況,為耐藥結(jié)核病疫情控制提供科學(xué)依據(jù)。方法:采用比例法檢測(cè)375例耐多藥肺結(jié)核患者臨床分離株對(duì)Ofx、Km二線抗結(jié)核藥物的耐藥性,回顧性分析其耐藥情況。結(jié)果:375例耐多藥肺結(jié)核,對(duì)Km耐藥占12.8%(48例),對(duì)Ofx耐藥占39.73%(149例),對(duì)于Ofx、Km的兩種二線抗結(jié)核藥物同時(shí)耐藥(XDR-TB)的比例達(dá)到8.53%(32例)。在不同登記分類耐多藥肺結(jié)核病例二線藥敏結(jié)果中,復(fù)治病例則對(duì)Ofx耐藥明顯高于初治。在XDR-TB病例中,復(fù)發(fā)、復(fù)治失敗病例占75%,明顯高于其他類別來(lái)源病例。結(jié)論:耐多藥結(jié)核分枝桿菌菌株對(duì)二線抗結(jié)核藥物具有較高的耐藥率,有必要進(jìn)一步加強(qiáng)實(shí)驗(yàn)室對(duì)二線抗結(jié)核藥物敏感性的檢測(cè)能力。同時(shí)應(yīng)加強(qiáng)對(duì)肺結(jié)核患者的治療管理,避免不規(guī)則治療及藥物濫用,及早控制廣泛耐多藥肺結(jié)核產(chǎn)生。
[Abstract]:Objective: to understand the drug resistance of multidrug resistant Mycobacterium tuberculosis (MTB) to ofloxacin (Ofx) and kanamycin (Km) second-line anti tuberculosis drugs, and to provide scientific basis for the control of the epidemic situation of drug-resistant tuberculosis. Methods: the resistance of 375 patients with multi drug resistant pulmonary tuberculosis to Ofx and Km second line anti tuberculosis drugs was analyzed by proportion method. Results: 375 cases of multidrug-resistant pulmonary tuberculosis accounted for 12.8% (48 cases) of Km resistance and 39.73% (149 cases) against Ofx, and 8.53% (32 cases) for Ofx and two second line anti tuberculosis drug resistance (XDR-TB) in Km. In the second line drug sensitivity results of different registered multi drug lung nodules, the retreated cases were significantly higher than those of Ofx. In XDR-TB cases, the recurrence and retreatment failed cases accounted for 75%, obviously higher than other types of sources. Conclusion: multi drug resistant Mycobacterium tuberculosis strains have high drug resistance rate to the second line anti tuberculosis drugs. It is necessary to further strengthen the laboratory's ability to detect the sensitivity of the second line anti tuberculosis drugs. Meanwhile, the patients with tuberculosis should be strengthened. The treatment and management should avoid irregular treatment and drug abuse, and control the occurrence of multidrug-resistant tuberculosis in an early stage.

【作者單位】： 廣東省結(jié)核病控制中心;
【基金】：廣東省醫(yī)學(xué)科研基金項(xiàng)目(編號(hào):A2013113) 中國(guó)全球基金結(jié)核病項(xiàng)目(編號(hào):CHN-S10-G14-T)
【分類號(hào)】：R521
，

本文編號(hào)：1846482